Skip to Main Content

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood
Blood Advances
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current issue
- All Issues
CME
About

Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2014, Issue 1

December 5 2014

In this Issue

Ham-Wasserman Manuscript
Acute Myeloid Leukemia in the Elderly Patient
Biologically Based Acute Leukemia Therapy: 2014 and Beyond
Comeback Kid: The Contact Pathway and Factor XI
Current and Future Therapies for Aplastic Anemia and Myelodysplastic Syndromes
“Double Hit” Diffuse Large B-Cell Lymphoma
Genetics of Chronic Lymphocytic Leukemia and Lymphoplasmacytic Lymphoma
Hodgkin Lymphoma Prognosis and Therapy
Indolent Lymphoma: Microenvironment
Insights from Pediatric Hematologic Malignancies: Focus on Acute Lymphocytic Leukemia
- Evidence-Based Mini-Review
Iron Homeostasis & Chronic Disease: Disorders of Iron Overload
Minimal Residual Disease: Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia
- Evidence-Based Mini-Review
Myeloma: Controversies in Therapy
Myeloproliferative Neoplasms: Ten Years After JAK2-V617F
New Paradigms in Anticoagulation and Thrombolysis
- Evidence-Based Mini-Review
Nontraditional Laboratory Assays of Hemostasis: What the Consulting Hematologist Should Know
- Evidence-Based Mini-Review
Platelet Disorders: Managing Too Many, Too Few
Practice Issues in Hemophilia
Reproductive Reasoning: Hematology and Reproduction
Secret Lives of Blood Cells in Disease
Sickle Cell Disease: Treating Patients with Broken Red Cells
- Evidence-Based Mini-Review
Spin Doctors: Apheresis for Hematologists
Stemware: Stem Cell Therapy for Congenital Blood Disorders
Survivorship in Hematologic Malignancies
Targeted Oral Anticoagulants: Skating on Thin Ice with Blood Thinners
- Evidence-Based Mini-Review
Therapeutic Progress in von Willebrand Disease
Transfusion Medicine-Transfusible Assets (AABB Joint Session)
Transplantation: Adoptive T-Cell Strategies
Viruses and Lymphoma
ASH Choosing Wisely®
Errata

Table of Contents

Ham-Wasserman Manuscript

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel

Acute Myeloid Leukemia in the Elderly Patient

Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia

Heidi D. Klepin

Treating acute myeloid leukemia in older adults

Eunice S. Wang

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Mohamed L. Sorror,Elihu Estey

Biologically Based Acute Leukemia Therapy: 2014 and Beyond

Intermediate-risk acute myeloid leukemia therapy: current and future

Konstanze Döhner,Peter Paschka

Epigenetic targeting and personalized approaches for AML

Gail J. Roboz

Comeback Kid: The Contact Pathway and Factor XI

Future prospects for contact factors as therapeutic targets

David Gailani

Recent insights into the role of the contact pathway in thrombo-inflammatory disorders

Maurits L. van Montfoort,Joost C.M. Meijers

Epidemiologic and clinical data linking factors XI and XII to thrombosis

Nigel S. Key

Current and Future Therapies for Aplastic Anemia and Myelodysplastic Syndromes

Biology of BM failure syndromes: role of microenvironment and niches

Sophia R. Balderman,Laura M. Calvi

Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Corey Cutler

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres,Aaron T. Gerds

“Double Hit” Diffuse Large B-Cell Lymphoma

Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC

Steven H. Swerdlow

Impact of MYC on malignant behavior

German Ott

Double-hit lymphomas: current paradigms and novel treatment approaches

Kieron Dunleavy

Genetics of Chronic Lymphocytic Leukemia and Lymphoplasmacytic Lymphoma

Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis

Davide Rossi

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53

Clive S. Zent,W. Richard Burack

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma

Adrian Wiestner

Hodgkin Lymphoma Prognosis and Therapy

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Andrew M. Evens,Lale Kostakoglu

The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling

David W. Scott,Christian Steidl

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Solomon A. Graf,Ajay K. Gopal

Indolent Lymphoma: Microenvironment

Indolent lymphoma: follicular lymphoma and the microenvironment—insights from the microscope

Nancy Lee Harris

Indolent lymphoma: follicular lymphoma and the microenvironment—insights from gene expression profiling

Lisa M. Rimsza,Melba C. Jaramillo

Therapeutic targeting of microenvironment in follicular lymphoma

Grzegorz S. Nowakowski,Stephen M. Ansell

Insights from Pediatric Hematologic Malignancies: Focus on Acute Lymphocytic Leukemia

The genomic landscape of acute lymphoblastic leukemia in children and young adults

Charles G. Mullighan

Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia

Sarah Alexander

Balancing cure and long-term risks in acute lymphoblastic leukemia

Lewis B. Silverman

Evidence-Based Mini-Review

CNS prophylaxis in pediatric acute lymphoblastic leukemia

Edward Allan R. Sison,Lewis B. Silverman

Iron Homeostasis & Chronic Disease: Disorders of Iron Overload

Iron clad: iron homeostasis and the diagnosis of hereditary iron overload

Matthew M. Heeney

Guidelines for quantifying iron overload

John C. Wood

Iron age: novel targets for iron overload

Carla Casu,Stefano Rivella

Minimal Residual Disease: Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

David Grimwade,Sylvie D. Freeman

Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?

Michael J. Mauro

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Martin Schrappe

Evidence-Based Mini-Review

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

David T. Yeung,Michael J. Mauro

Myeloma: Controversies in Therapy

All transplantation-eligible patients with myeloma should receive ASCT in first response

Philippe Moreau,Michel Attal

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson,Jacob P. Laubach,Nikhil C. Munshi,Kenneth C. Anderson

A practical approach to relapsed multiple myeloma

Joseph R. Mikhael

Myeloproliferative Neoplasms: Ten Years After JAK2-V617F

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen,Ann Mullally

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer,Ruben A. Mesa

The evolving genomic landscape of myeloproliferative neoplasms

Jyoti Nangalia,Tony R. Green

New Paradigms in Anticoagulation and Thrombolysis

New insights into treatment of venous thromboembolism

Stephan Moll

Central venous catheter–related thrombosis

William Geerts

Prevention and treatment of venous thromboembolism in patients with cancer

Agnes Y.Y. Lee

Evidence-Based Mini-Review

Management of incidental splanchnic vein thrombosis in cancer patients

Lisa Baumann Kreuziger,Walter Ageno,Agnes Lee

Nontraditional Laboratory Assays of Hemostasis: What the Consulting Hematologist Should Know

Laboratory methods to detect antiphospholipid antibodies

Steven A. Krilis,Bill Giannakopoulos

Monitoring target-specific oral anticoagulants

Barbara A. Konkle

Evidence-Based Mini-Review

What is the effect of rivaroxaban on routine coagulation tests?

Deborah M. Siegal,Barbara A. Konkle

Platelet Disorders: Managing Too Many, Too Few

Genetic basis of congenital platelet disorders

Jesse Hinckley,Jorge Di Paola

Pharmacogenomics of antiplatelet drugs

Marc S. Sabatine,Jessica L. Mega

Management of MPN beyond JAK2

Claire N. Harrison,Natalia Curto Garcia

Practice Issues in Hemophilia

Lasting power of new clotting proteins

Jerry S. Powell

Toward optimal therapy for inhibitors in hemophilia

Christine L. Kempton,Shannon L. Meeks

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses

Birgit M. Reipert

Reproductive Reasoning: Hematology and Reproduction

Anticoagulation and in vitro fertilization and ovarian stimulation

Shannon M. Bates

Pregnancy and venous thromboembolism: ‘TIPPS’ for risk stratification

Marc Rodger

Anticoagulation in pregnancy complications

Saskia Middeldorp

Secret Lives of Blood Cells in Disease

Platelets: more than a sack of glue

Andrew S. Weyrich

RBCs as targets of infection

Jeffrey McCullough

Flamethrowers: blood cells and cancer thrombosis risk

Ingrid Pabinger,Florian Posch

Sickle Cell Disease: Treating Patients with Broken Red Cells

Reproductive issues in sickle cell disease

Kim Smith-Whitley

Pulmonary hypertension in sickle cell disease: diagnosis and management

Kenneth I. Ataga,Elizabeth S. Klings

Breakthrough: new guidance for silent cerebral ischemia and infarction in sickle cell disease

Charles T. Quinn

Evidence-Based Mini-Review

Does hydroxyurea prevent pulmonary complications of sickle cell disease?

Tyler W. Buckner,Kenneth I. Ataga

Spin Doctors: Apheresis for Hematologists

Thrombotic microangiopathy and indications for therapeutic plasma exchange

Jill Adamski

Red cell exchange: special focus on sickle cell disease

Haewon C. Kim

Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia

Nicole Aqui,Una O'Doherty

Stemware: Stem Cell Therapy for Congenital Blood Disorders

Replacing bad (F)actors: hemophilia

Christopher B. Doering,H. Trent Spencer

Smoothing the crescent curve: sickle cell disease

Julie-An Talano,Mitchell S. Cairo

Eliminating SCID row: new approaches to SCID

Donald B. Kohn

Survivorship in Hematologic Malignancies

Optimal disease surveillance strategies in non-Hodgkin lymphoma

Jonathon B. Cohen,Christopher R. Flowers

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Andrea K. Ng

Caring for the long-term survivor after allogeneic stem cell transplantation

Smita Bhatia

Targeted Oral Anticoagulants: Skating on Thin Ice with Blood Thinners

Bleeding complications of targeted oral anticoagulants: what is the risk?

Michael Levine,Joshua N. Goldstein

The target-specific oral anticoagulants: practical considerations

David A. Garcia

Reversing targeted oral anticoagulants

Maureane Hoffman,Dougald M. Monroe

Evidence-Based Mini-Review

What is the role of hemodialysis for dabigatran-associated major bleeding?

Benjamin Kim,David A. Garcia

Therapeutic Progress in von Willebrand Disease

Clinical and laboratory diagnosis of VWD

Augusto B. Federici

New insights into genotype and phenotype of VWD

Veronica H. Flood

Management of VWD

Anne T. Neff,Robert F. Sidonio, Jr

Transfusion Medicine-Transfusible Assets (AABB Joint Session)

The science behind the hypoxic niche of hematopoietic stem and progenitors

César Nombela-Arrieta,Leslie E. Silberstein

Transfusion strategies in hematologic and nonhematologic disease

Jeffrey L. Carson,Roger Strair

Bloodless medicine: what to do when you can't transfuse

Linda M.S. Resar,Steven M. Frank

Transplantation: Adoptive T-Cell Strategies

Chimeric antigen receptor T-cell therapy for ALL

Shannon L. Maude,Elizabeth J. Shpall,Stephan A. Grupp

Cytotoxic T lymphocytes for leukemia and lymphoma

Catherine M. Bollard,A. John Barrett

Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions

Sarah Nikiforow,Edwin P. Alyea

Viruses and Lymphoma

Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy

Shigeru Kusumoto,Kensei Tobinai

HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options

Amrita Krishnan,John A. Zaia

Hepatitis C virus-associated B-cell non-Hodgkin lymphomas

Barbara Vannata,Emanuele Zucca

ASH Choosing Wisely®

Five hematologic tests and treatments to question

Lisa K. Hicks,Harriet Bering,Kenneth R. Carson,Adam E. Haynes,Judith Kleinerman,Vishal Kukreti,Alice Ma,Brigitta U. Mueller,Sarah H. O'Brien,Julie A. Panepinto,Marcelo C. Pasquini,Anita Rajasekhar,Ravi Sarode,William A. Wood

Errata

Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology Am Soc Hematol Educ Program. 2013;2013:138-150.

Cover Image

Cover Image

Cover: Conceptual image of sickle cell anemia with red blood cells. © Stocktrek Images/Corbis.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

Latest
Most Read
Most Cited

Clinical screening for Ph-like ALL and the developing role of TKIs

Perioperative hemostasis for patients with hemophilia

Evidence-based management of pregnant women with sickle cell disease in high-income countries

Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy

Optimal approach to T-cell ALL

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright ©2023 by American Society of Hematology

Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account